Companies: 10,795·Total market cap: $144.5T
OKYO Pharma Limited

OKYO Pharma Limited

OKYONASDAQHealthcare● Active
$1.59
$-0.03(-1.85%)
Market Cap$61003644
P/E Ratio—
52W High$3.349
52W Low$1.44
Overview
Foreign Private Issuer · Files 20-F / 6-K

OKYO Pharma Limited (OKYO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001849296 · OKYO · NASDAQ · as of Jun 9, 2026

Filing snapshot

271
Total Filings
3
Latest Form
2026-06-02
Most Recent
2022
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001849296 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2025-07-18
Fiscal Year End
Jul 18, 2025
Accession No.
0001641172-25-020240
Primary Document
form20-f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001849296 · Accession 0001641172-25-020240

Latest Key Filings

6-KQuarterly Report
6-K
2026-05-19
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
3Initial Statement of Beneficial Ownership
3
2026-06-02
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-06-01
View
3Initial Statement of Beneficial Ownership
3
2026-06-01
View
3Initial Statement of Beneficial Ownership
3
2026-05-22
View
3Initial Statement of Beneficial Ownership
3
2026-05-22
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-19
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-29
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-07
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-03-19
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-03-19
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-03-19
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-18
View
Showing 1–15 of 264 filingsForm 4 / 144 hidden· 271 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001849296  |  Exchange: NASDAQ · Healthcare

OKYO Pharma Limited (NASDAQ: OKYO) has submitted 271 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2022. As a Healthcare sector company with CIK 0001849296, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is OKYO Pharma Limited's most comprehensive regulatory disclosure. The most recent OKYO Pharma Limited 10-K was filed on 2025-07-18 for fiscal year ending 2025. Historical OKYO 10-K annual reports are available from 2021 through 2025.

Investors researching OKYO Pharma Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
IMMX SEC Filings →ZNTL SEC Filings →MGNX SEC Filings →SLGL SEC Filings →WHWK SEC Filings →COYA SEC Filings →TLSA SEC Filings →PLRX SEC Filings →
→ OKYO Financials→ OKYO Earnings→ OKYO Insider Trades

Frequently Asked Questions

OKYO SEC Filings · 8 questions

OKYO Pharma Limited (OKYO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 271 filings and access original documents at no cost. OKYO Pharma Limited's CIK is 0001849296.

OKYO SEC filingsOKYO Pharma Limited SEC documentsfind OKYO 10-K